Below are pilot data from a phase one randomized clinical trial where patients with schizophrenia were tested for the benefits of a new injectable antipsychotic medication compared to patients receiving a traditional oral antipsychotic medication or were part of a waitlist control group standard inpatient care and anticipating antipsychotic treatment. Patients were tested one-month after the clinical trial was initiated using a battery of neurological and physiological measures including a quantified thought disorder measure. The data are presented below where higher values indicate more disordered thought processing. Is there evidence of a difference in disordered thinking between the three treatment groups? α = 0.05. This is an Independent Sample ANOVA:F distribution Waitlist Oral AP Injectable AP 89 70 51 92 66 47 86 70 49 79 62 57 88 68 41 77 55 46 92 63 53
Below are pilot data from a phase one randomized clinical trial where patients with schizophrenia were tested for the benefits of a new injectable antipsychotic medication compared to patients receiving a traditional oral antipsychotic medication or were part of a waitlist control group standard inpatient care and anticipating antipsychotic treatment. Patients were tested one-month after the clinical trial was initiated using a battery of neurological and physiological measures including a quantified thought disorder measure. The data are presented below where higher values indicate more disordered thought processing. Is there evidence of a difference in disordered thinking between the three treatment groups? α = 0.05.
This is an Independent Sample ANOVA:F distribution
| Waitlist | Oral AP | Injectable AP |
| 89 | 70 | 51 |
| 92 | 66 | 47 |
| 86 | 70 | 49 |
| 79 | 62 | 57 |
| 88 | 68 | 41 |
| 77 | 55 | 46 |
| 92 | 63 | 53 |
Step by step
Solved in 2 steps with 3 images
